Biologics Set to Transform India’s Pharmaceutical Future, But Experts Say Regulatory Evolution Will Be Key
As India emerges as a global biotechnology hub, scientists and industry experts believe a modern, risk-based regulatory framework will determine its long-term success
By Suman Munshi | IBG NEWS Special Report
Kolkata: The next revolution in healthcare may not come from conventional chemical drugs but from biologics—advanced medicines developed from living cells that are rapidly changing the treatment of cancer, autoimmune disorders, rare diseases, and genetic conditions. As global demand for biologics continues to rise, experts believe India is well-positioned to become a major international player, provided its regulatory ecosystem evolves alongside scientific innovation.
India has already established itself as one of the world’s largest producers of generic medicines and vaccines. However, biologics represent a far more complex field where the manufacturing process itself determines the quality and safety of the final product. Unlike traditional medicines, biologics cannot simply be copied through chemical synthesis, making regulatory oversight significantly more challenging.
A New Generation of Medicines
Biologics include monoclonal antibodies, recombinant proteins, vaccines, cell therapies, gene therapies, and other advanced biological products. Their development requires expertise in biotechnology, molecular biology, immunology, bioinformatics, and advanced manufacturing.
Industry analysts believe the future pharmaceutical market will increasingly shift toward these high-value therapies as precision medicine becomes more common worldwide.
Development is a Long Scientific Journey
The journey of a biologic begins with identifying the biological mechanism responsible for a disease. Scientists then discover and optimize a candidate molecule before developing a stable production cell line capable of manufacturing the medicine consistently.
The product subsequently undergoes process development, analytical characterization, laboratory evaluation, preclinical studies, regulatory review, and multi-phase clinical trials before receiving marketing authorization. Even after approval, manufacturers must continue long-term safety monitoring through pharmacovigilance systems.
Experts often describe biologics by saying:
“The process is the product.”
Any variation in manufacturing conditions may alter the biological characteristics of the medicine, making continuous quality control essential.
How a Biologic is Developed: The Complete Start-to-End Workflow
Unlike conventional medicines, biologics are developed through a highly regulated scientific process that may take 10–15 years and cost hundreds of millions of dollars. Every stage is closely monitored because even small manufacturing changes can alter the final product’s safety and effectiveness.
Stage 1: Disease Identification and Target Discovery
Scientists first study the disease and identify the biological pathway responsible for it. They determine which protein, receptor, gene, or immune mechanism can be targeted to treat the condition.
Objective: Find the most appropriate biological target.
Stage 2: Molecule Discovery
Researchers develop potential therapeutic molecules, such as:
- Monoclonal antibodies
- Recombinant proteins
- Cytokines
- Cell therapies
- Gene therapy vectors
Hundreds of candidates are screened before selecting the most promising one.
Objective: Identify the best therapeutic candidate.
Stage 3: Cell Line Development
The selected molecule is introduced into living cells capable of producing it consistently. Common production systems include:
- Chinese Hamster Ovary (CHO) cells
- Yeast
- Bacteria
- Mammalian cell cultures
The manufacturing cell line must remain genetically stable.
Objective: Create a reliable biological production system.
Stage 4: Process Development
Scientists optimize the manufacturing process by controlling:
- Cell culture conditions
- Nutrient composition
- Temperature
- pH
- Fermentation parameters
- Purification techniques
This stage determines the quality of the final medicine.
Objective: Build a scalable and reproducible manufacturing process.
Stage 5: Analytical Characterization
Advanced technologies are used to verify the product’s identity and quality:
- Mass spectrometry
- Chromatography
- Glycosylation analysis
- Potency assays
- Structural characterization
For biologics, analytical evidence is often the foundation of regulatory evaluation.
Objective: Demonstrate molecular consistency.
Stage 6: Preclinical Studies
Laboratory and animal studies evaluate:
- Toxicity
- Pharmacology
- Immunogenicity
- Dose-response
- Biological activity
These studies establish initial safety before human testing.
Objective: Generate evidence for clinical trial approval.
Stage 7: Regulatory Submission
Developers submit detailed scientific data covering:
- Manufacturing process
- Quality control
- Preclinical findings
- Clinical protocols
- Risk assessments
Regulatory authorities review the package before permitting human trials.
Objective: Obtain authorization to begin clinical development.
Stage 8: Clinical Trials
Phase I
- Small group of volunteers
- Safety evaluation
- Dose determination
Phase II
- Patients with the disease
- Preliminary efficacy
- Dose optimization
Phase III
- Large multicenter studies
- Confirmation of safety and efficacy
- Statistical validation
For biosimilars, regulators increasingly apply a risk-based approach, relying heavily on analytical similarity while tailoring clinical requirements to the scientific evidence.
Objective: Demonstrate that benefits outweigh risks.
Stage 9: Regulatory Review and Approval
Authorities evaluate the totality of evidence, including:
- Quality
- Safety
- Efficacy
- Manufacturing consistency
- Risk management plans
Only after a successful review is marketing authorization granted.
Objective: Ensure the medicine is safe and effective for patients.
Stage 10: Commercial Manufacturing
Production continues under strict Good Manufacturing Practices (GMP):
- Batch testing
- Environmental monitoring
- Sterility assurance
- Process validation
- Quality assurance
Every batch must meet predefined specifications.
Objective: Maintain consistent product quality.
Stage 11: Post-Marketing Surveillance
Approval is not the end of regulation. Continuous monitoring includes:
- Adverse event reporting
- Immunogenicity surveillance
- Real-world effectiveness
- Long-term safety studies
- Product traceability
Regulators may require additional studies or update product labeling based on emerging evidence.
Objective: Protect patient safety throughout the product’s lifecycle.
Comparison of Biologics Regulatory Frameworks: FDA vs EMA vs India (CDSCO/DCGI)
| Regulatory Aspect | US FDA | European Medicines Agency (EMA) | India (CDSCO/DCGI) | Recommended Future for India |
|---|---|---|---|---|
| Regulatory Philosophy | Science and risk-based | Science and harmonization across EU | Science-based with evolving biosimilar guidelines | Risk-based, innovation-friendly, patient-centric |
| Primary Legislation | Public Health Service Act & BPCIA | EU Pharmaceutical Legislation | Drugs & Cosmetics Act, NDCT Rules, Similar Biologics Guidelines | Dedicated Biologics Act/Framework |
| Approval Pathway | BLA (Biologics License Application) | Centralized Marketing Authorization | New Drug/Biologic approval through CDSCO/DCGI | Dedicated biologics approval pathway |
| Analytical Characterization | Extensive and highly detailed | Extensive and highly detailed | Required but continuously evolving | Greater reliance on advanced analytical technologies |
| Clinical Trial Requirement | Risk-based; may reduce studies with strong analytical evidence | Risk-based approach | Case-specific according to guidelines | Adaptive and science-driven clinical requirements |
| Biosimilar Evaluation | Totality of Evidence approach | Totality of Evidence approach | Comparative quality, non-clinical and clinical evaluation | Greater emphasis on analytical similarity and real-world evidence |
| Interchangeability Status | Separate designation available | Determined by individual member states | No dedicated interchangeability designation | Develop scientific interchangeability framework |
| Manufacturing Oversight | Strict GMP with frequent inspections | EU GMP compliance | GMP inspections and regulatory oversight | Digital GMP, continuous manufacturing monitoring |
| Quality by Design (QbD) | Widely implemented | Widely encouraged | Increasing adoption | Mandatory QbD integration |
| Data Integrity Requirements | Extremely stringent | Very stringent | Strengthening compliance | AI-assisted data integrity monitoring |
| Pharmacovigilance | Comprehensive lifecycle monitoring | Strong EU-wide surveillance | National PvPI system | National biologics registry with AI signal detection |
| Real-World Evidence (RWE) | Increasing regulatory acceptance | Growing acceptance | Limited utilization | Structured national RWE platform |
| Artificial Intelligence Usage | Emerging in review and surveillance | Gradually expanding | Limited regulatory integration | AI-assisted regulatory review and safety analytics |
| Review Timelines | Standard and expedited pathways available | Standard and accelerated pathways | Standard regulatory review | Fast-track pathway for breakthrough biologics |
| Innovation Support | Fast Track, Breakthrough Therapy, Accelerated Approval | PRIME and accelerated assessment | Limited dedicated mechanisms | Regulatory sandbox and innovation pathway |
| Lifecycle Management | Continuous regulatory oversight | Continuous lifecycle management | Post-approval monitoring | Digital lifecycle management system |
| Global Harmonization | High alignment with ICH | High alignment with ICH | Progressive alignment | Full harmonization while addressing Indian healthcare needs |
| Regulatory Strength | Global benchmark | Global benchmark | Rapidly evolving | Become a global benchmark for affordable biologics |
Key Takeaway
FDA Model
- Strong emphasis on analytical science
- Risk-based regulation
- Extensive post-marketing surveillance
- Encourages innovation while maintaining patient safety
EMA Model
- Harmonized scientific evaluation across Europe
- Strong lifecycle management
- Collaborative regulatory approach
Current Indian Model
- Significant progress through CDSCO/DCGI and Similar Biologics Guidelines
- Growing scientific capability
- Needs stronger digital infrastructure, advanced analytics, and adaptive regulatory pathways
The Way Forward for India
Experts suggest India should not simply replicate the FDA or EMA models. Instead, it should develop a hybrid regulatory framework that:
- Aligns with global scientific standards,
- Supports affordable innovation,
- Utilizes AI and real-world evidence,
- Strengthens pharmacovigilance,
- Encourages domestic biotechnology research while ensuring the highest standards of patient safety.
In short:
“India should aim not only to manufacture biologics for the world, but also to become a global leader in biologics regulation and innovation.”
Biologics Development Workflow (At a Glance)
Why This Matters
Experts often summarize biologics with a simple but powerful statement:
“For biologics, the process is the product.”
Unlike conventional chemical medicines, even minor manufacturing changes can influence a biologic’s structure and clinical performance. Therefore, the future of biologics depends not only on scientific innovation but also on robust, lifecycle-based regulatory oversight.
Why India Needs a Different Regulatory Approach
Many experts argue that India should simply adopt the U.S. Food and Drug Administration (FDA) model for biologics regulation. However, regulatory specialists suggest that while international scientific standards should guide Indian policy, the country’s healthcare environment requires its own tailored approach.
India faces different challenges, including:
- A large and diverse patient population
- Cost-sensitive healthcare delivery
- Expanding domestic biotechnology manufacturing
- Growing startup ecosystem
- Public health priorities distinct from Western markets
Therefore, regulators must balance innovation, affordability, and patient safety.
FDA Model vs Indian Requirements
The FDA follows a science-driven approach emphasizing extensive analytical characterization, risk-based clinical development, lifecycle quality management, and continuous post-marketing surveillance.
India’s regulatory framework, administered through the Central Drugs Standard Control Organization (CDSCO) and the Drugs Controller General of India (DCGI), has made significant progress in establishing guidelines for similar biologics. Nevertheless, experts believe future regulations should further strengthen advanced analytical evaluation, manufacturing oversight, digital pharmacovigilance, and real-world evidence generation.
Rather than replicating foreign systems, India has the opportunity to build a framework that combines global scientific standards with local healthcare realities.
Recommendations for India’s Future
Healthcare and regulatory experts suggest several priorities:
- Adoption of risk-based regulatory review
- Stronger Good Manufacturing Practice (GMP) oversight
- Greater use of advanced analytical technologies
- National biologics safety and pharmacovigilance databases
- Faster approval pathways for breakthrough therapies
- Increased collaboration between academia, industry, and regulators
- Greater use of artificial intelligence for quality assessment and safety monitoring
Such reforms could enhance patient safety while accelerating innovation and reducing development timelines.
Opportunity for India
India’s biotechnology ecosystem is expanding rapidly, supported by skilled scientific talent, competitive manufacturing costs, and growing investment in research and development. Combined with experience gained through vaccine production and biosimilars, these strengths position the country to become a global center for biologics manufacturing and innovation.
However, experts caution that future leadership will depend not only on scientific capability but also on regulatory credibility. Transparent, predictable, and science-based regulation will be essential for attracting investment, expanding exports, and building international confidence in Indian biologics.
Looking Ahead
As the global pharmaceutical industry transitions toward advanced biological therapies, India stands at a critical crossroads. The nation already possesses the manufacturing foundation and scientific expertise required to compete internationally. The next challenge is to create a regulatory system that promotes innovation without compromising safety.
If achieved, India could move beyond being known as the “Pharmacy of the World” to becoming one of the world’s leading centers for biologics research, development, and advanced healthcare innovation.
About the Author
Suman Munshi is the Founder and Editorial Leader of IBG NEWS and has more than 25 years of experience in information technology, Pharma & Hitech R&D laboratory informatics (LIMS), digital transformation, regulatory compliance, and digital journalism. With academic training in Post Graduate Computer Science from NIELIT, GxP Certified from the USA, UK, and Ireland. He also has an ISO17025 Lab operation Certificate from Ireland, and professional experience in regulated industries in MNCs of the Global Top 5 of Pharma world. He writes extensively on biotechnology, healthcare policy, pharmaceutical regulation, artificial intelligence, and emerging technologies, advocating evidence-based governance that balances innovation with patient safety.
